Universe Pharmaceuticals INC Deferred Income Tax Expense (Benefit)
Universe Pharmaceuticals INC (UPC) reported Deferred Income Tax Expense (Benefit) of $606.70 million for the 12-month period ending 2024-09-30, per its 20-F filed 2026-01-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-01-29
| Period end | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|
| 2024-09-30 | $606.70M 20-F · filed 2026-01-29 | $606.70K 20-F · filed 2025-04-29 | |
| 2024-03-31 | $665.15K 6-K · filed 2024-09-20 | ||
| 2023-09-30 | $1.57B 20-F · filed 2026-01-29 | $679.59K 20-F · filed 2024-01-30 | |
| 2023-03-31 | $556.87K 6-K · filed 2024-09-20 | ||
| 2022-09-30 | -$542.38K 20-F · filed 2025-04-29 | -$605.28K 20-F · filed 2023-02-10 | |
| 2022-03-31 | -$100.41K 6-K · filed 2023-08-31 | ||
| 2021-09-30 | -$668.34K 20-F · filed 2024-01-30 | ||
| 2021-03-31 | $71.22K 6-K · filed 2022-08-16 | ||
| 2020-09-30 | -$9.89K 20-F · filed 2023-02-10 | ||
| 2019-09-30 | -$39.63K 20-F · filed 2022-01-31 |